ES2181902T3 - Derivados de 4,5-diaril-oxazol. - Google Patents

Derivados de 4,5-diaril-oxazol.

Info

Publication number
ES2181902T3
ES2181902T3 ES96924137T ES96924137T ES2181902T3 ES 2181902 T3 ES2181902 T3 ES 2181902T3 ES 96924137 T ES96924137 T ES 96924137T ES 96924137 T ES96924137 T ES 96924137T ES 2181902 T3 ES2181902 T3 ES 2181902T3
Authority
ES
Spain
Prior art keywords
sup
diaril
oxazol
derivatives
carboxi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96924137T
Other languages
English (en)
Inventor
Kiyoshi Taniguchi
Kouji Hattori
Kazunori Tsubaki
Osamu Okitsu
Seiichiro Tabuchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9515085.0A external-priority patent/GB9515085D0/en
Priority claimed from AUPN9002A external-priority patent/AUPN900296A0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2181902T3 publication Critical patent/ES2181902T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE DESCRIBEN COMPUESTOS HETEROCICLICOS DE FORMULA (I), EN LA CUAL R SUP,1} ES CARBOXI O CARBOXI PROTEGIDO, R SUP,2} ES ARILO QUE PUEDE PRESENTAR UN SUSTITUYENTE(S) ADECUADO, R SUP,3} ES ARILO QUE PUEDE PRESENTAR UN SUSTITUYENTE(S) ADECUADO, R SUP,4} ES HIDROGENO, ALQUILO INFERIOR, HIDROXI O ARILO, A SUP,1} ES ALQUILENO INFERIOR, (A) ES (B), ETC., ETC., Y N ES 0 O 1, Y LAS SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, QUE RESULTAN UTILES COMO MEDICAMENTO.
ES96924137T 1995-07-21 1996-07-18 Derivados de 4,5-diaril-oxazol. Expired - Lifetime ES2181902T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9515085.0A GB9515085D0 (en) 1995-07-21 1995-07-21 Heterocyclic compounds
AUPN9002A AUPN900296A0 (en) 1996-03-29 1996-03-29 Heterocyclic compounds

Publications (1)

Publication Number Publication Date
ES2181902T3 true ES2181902T3 (es) 2003-03-01

Family

ID=25645150

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96924137T Expired - Lifetime ES2181902T3 (es) 1995-07-21 1996-07-18 Derivados de 4,5-diaril-oxazol.

Country Status (17)

Country Link
US (2) US5972965A (es)
EP (2) EP1213285A3 (es)
JP (1) JPH11509191A (es)
KR (1) KR19990063582A (es)
CN (1) CN1095839C (es)
AT (1) ATE224380T1 (es)
AU (1) AU716304B2 (es)
CA (1) CA2227442A1 (es)
DE (1) DE69623785T2 (es)
DK (1) DK0842161T3 (es)
EA (1) EA002156B1 (es)
ES (1) ES2181902T3 (es)
HU (1) HUP9900881A3 (es)
MX (1) MX9800577A (es)
PT (1) PT842161E (es)
TW (1) TW401408B (es)
WO (1) WO1997003973A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO713297A0 (en) 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
GB9720270D0 (en) 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
AUPP003297A0 (en) 1997-10-27 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazole compounds
AUPP029197A0 (en) 1997-11-10 1997-12-04 Fujisawa Pharmaceutical Co., Ltd. Benzocycloheptene derivatives
AUPP109097A0 (en) 1997-12-22 1998-01-22 Fujisawa Pharmaceutical Co., Ltd. Napthalene derivatives
DE19801648A1 (de) * 1998-01-17 1999-07-22 Bayer Ag alpha-Substituierte Lactone
GB9804426D0 (en) * 1998-03-02 1998-04-29 Pfizer Ltd Heterocycles
AUPP608898A0 (en) * 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
US6335459B1 (en) 1998-12-23 2002-01-01 Syntex (U.S.A.) Llc Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators
JP4834224B2 (ja) 1999-03-05 2011-12-14 デューク ユニバーシティ Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体
AU5249200A (en) * 1999-06-21 2001-01-09 Fujisawa Pharmaceutical Co., Ltd. Remedies for skin ulcer
US6894175B1 (en) * 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
AUPQ253199A0 (en) * 1999-08-30 1999-09-23 Fujisawa Pharmaceutical Co., Ltd. Non-prostanoid prostaglandin I2-agonist
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
CA2444563A1 (en) * 2001-04-18 2002-10-31 Fujisawa Pharmaceutical Co., Ltd. Tissue fibrosis inhibitors
NZ528820A (en) 2001-04-19 2007-01-26 Eisai Co Ltd 2-iminopyrrolidine derivatives
WO2003074483A1 (fr) * 2002-03-05 2003-09-12 Ono Pharmaceutical Co., Ltd. Composes derives de 8 azaprostaglandine et medicaments contenant ceux-ci comme principe actif
NZ535748A (en) * 2002-04-12 2007-06-29 Pfizer Use of EP4 receptor ligands in the treatment of IL-6 involved diseases
KR100468352B1 (ko) * 2002-09-24 2005-01-27 한국과학기술연구원 신규 피라졸로피리미딘계 유도체, 그의 제조방법 및 이를 유효성분으로 하는 약학적 조성물
JPWO2004069824A1 (ja) 2003-02-07 2006-05-25 第一製薬株式会社 ピラゾール誘導体
EP2444393A1 (en) 2003-02-19 2012-04-25 Eisai R&D Management Co., Ltd. Methods for producing cyclic benzamidine derivatives
US7557095B2 (en) 2006-05-12 2009-07-07 Allergan, Inc. Therapeutic compounds
WO2010010909A1 (ja) 2008-07-23 2010-01-28 東レ株式会社 慢性腎不全処置剤
PL2343292T3 (pl) * 2008-09-10 2015-01-30 Agc Inc Nowa pochodna prostaglandyny I<sub>2</sub>
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
CN102917703B (zh) * 2010-03-08 2015-08-19 科研制药株式会社 新型ep4激动剂
SG188245A1 (en) 2010-08-20 2013-04-30 Allergan Inc Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
US20140073634A1 (en) * 2012-08-24 2014-03-13 Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center Heterocyclic modulators of hif activity for treatment of disease
EP2888253A4 (en) * 2012-08-24 2016-01-06 Univ Texas HETEROCYCLIC MODULATORS OF HIF FACTOR ACTIVITY USED FOR THE TREATMENT OF DISEASES
BR112015003729A2 (pt) 2012-08-24 2018-06-05 Univ Texas composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
ES2726648T3 (es) 2014-02-25 2019-10-08 Univ Texas Sales de moduladores heterocíclicos de la actividad del HIF para el tratamiento de enfermedades

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236474A (en) * 1989-12-20 1993-07-27 Bristol Myers Squibb Co 4,5-diphenyl-2-oxazole octanoic, nonanoic and decanoic acid and ester derivatives, preparation and pharmaceutical compositions thereof
US5187188A (en) * 1992-04-03 1993-02-16 Bristol-Myers Squibb Company Oxazole carboxylic acid derivatives
US5348969A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors
US5362879A (en) * 1993-04-15 1994-11-08 Bristol-Myers Squibb Company 4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation
CA2179399A1 (en) * 1993-12-20 1995-06-29 Kiyoshi Taniguchi 4,5-diaryloxazole derivatives
CN1057522C (zh) 1994-03-10 2000-10-18 藤泽药品工业株式会社 作为***素i2激动剂的萘衍生物

Also Published As

Publication number Publication date
EP0842161A1 (en) 1998-05-20
EA199800141A1 (ru) 1998-08-27
JPH11509191A (ja) 1999-08-17
TW401408B (en) 2000-08-11
EP1213285A3 (en) 2002-07-03
AU716304B2 (en) 2000-02-24
ATE224380T1 (de) 2002-10-15
CA2227442A1 (en) 1997-02-06
DK0842161T3 (da) 2003-01-27
KR19990063582A (ko) 1999-07-26
HUP9900881A2 (hu) 1999-08-30
DE69623785D1 (de) 2002-10-24
AU6469796A (en) 1997-02-18
CN1196726A (zh) 1998-10-21
EP0842161B1 (en) 2002-09-18
EP1213285A2 (en) 2002-06-12
WO1997003973A1 (en) 1997-02-06
DE69623785T2 (de) 2003-08-07
HUP9900881A3 (en) 2000-09-28
US6300344B1 (en) 2001-10-09
US5972965A (en) 1999-10-26
CN1095839C (zh) 2002-12-11
PT842161E (pt) 2003-02-28
MX9800577A (es) 1998-04-30
EA002156B1 (ru) 2001-12-24

Similar Documents

Publication Publication Date Title
ES2181902T3 (es) Derivados de 4,5-diaril-oxazol.
ES2161290T3 (es) Derivados de quinazolina.
PA8436201A1 (es) Derivados 6,5-heterobiciclicos sustituidos
AR007118A1 (es) 4(3h)-quinazolinonas 2,3 disustituidas y composiciones farmaceuticas que las contienen
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
ES2192213T3 (es) Arilalquil-diazinonas como inhibidores de fosfodiesterasa iv.
MY108885A (en) Heterocyclic-cyclic amine derivatives.
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
HUP0004592A2 (hu) VCAM-1 expresszió gátlására alkalmas vegyületek és eljárások
EA200000592A1 (ru) Азаполициклические соединения, конденсированные с арилом
ES2169127T3 (es) Nuevos carbamatos y ureas como modificadores de la resistencia multi-farmaco.
AR008853A1 (es) Nuevos compuestos farmaceuticamente activos, su uso en la fabricacion de medicamentos, metodo de tratamiento, composicion farmaceutica, compuestosintermediarios y proceso para la fabricacion de dichos compuestos
MX9300786A (es) Compuestos hipolipidaemicos.
ES2166470T3 (es) Derivados de indolalquilo de la benzodioxanmetilamina como ligandos de los receptores 5-ht1a.
ES2179996T3 (es) Cefalosporinas de vinil-pirrolidinona con sustituyentes basicos.
ES2142030T3 (es) Nuevos compuestos espiro-heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR016973A1 (es) Uso de aminometil-cromanos sustituidos para la produccion de un medicamento util para el tratamiento de enfermedades neurodegenerativas y para el estimulode la regeneracion neuronal
ES2071663T3 (es) Analogo de fluoxetina.
ES2098023T3 (es) Compuestos de estructura guanidinica y composiciones farmaceuticas que los contienen.
ES2058596T3 (es) Empleo de derivados de l-carnitina en el tratamiento terapeutico de alteraciones degenerativas del sistema nervioso.
NZ325259A (en) Phospholipid derivatives of phosphono-carboxylic acids, the production of said derivatives and the use of said derivatives as antiviral medicaments
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
ES2182090T3 (es) Nuevos derivados de pirrol.
AR027578A1 (es) Derivados de indano
ES2101373T3 (es) Tetrahidrociclopent(b)indol-metaminas y compuestos relacionados, un procedimiento para su preparacion y su uso como medicamentos.